Current Standard of Care and Treatment Options
At a Glance
Extranodal nasal NK/T-cell lymphoma (ENKTL) requires specialized treatment because it is naturally resistant to standard chemotherapy. L-asparaginase regimens, like DDGP or P-GEMOX, and concurrent chemoradiotherapy are the standard of care to effectively target these lymphoma cells.
Treating Extranodal nasal NK/T-cell lymphoma (ENKTL) requires a very specific approach. Because this lymphoma is biologically different from other types, “standard” lymphoma treatments often do not work [1]. Modern medicine has developed tailored protocols that have significantly improved outcomes for patients with both localized and advanced disease [2][3].
Why Standard Chemo (CHOP) Often Fails
In many common lymphomas, a regimen called CHOP (a combination of four drugs) is the go-to treatment. However, ENKTL cells produce a protein called P-glycoprotein (encoded by the MDR1 gene) [1][4]. This protein acts like a “pump” that sits on the surface of the cancer cell and literally pumps out the chemotherapy drugs before they can work [5]. This makes ENKTL naturally resistant to anthracyclines, a key drug class in the CHOP regimen [6].
The Essential “Backbone”: L-asparaginase
To bypass the “pumps” and kill the cancer, doctors use a drug called L-asparaginase (or its longer-acting version, pegaspargase) [3][7]. Unlike other drugs, L-asparaginase is not affected by the P-glycoprotein pump [8]. It works by starving the cancer cells of an amino acid (asparagine) they need to survive, making it the cornerstone of effective ENKTL treatment [9][10].
Treatment for Early-Stage Disease (I/II)
For lymphoma that is localized (usually in the nasal area), the goal is typically to cure the disease using a combination of chemotherapy and radiation [2].
- Concurrent Chemoradiotherapy (CCRT): This is currently the standard approach, where radiation and chemotherapy are given at the same time [7]. Giving them together has been shown to be more effective than giving one after the other [11].
- Consolidation: After the radiation and initial chemo are finished, patients often receive a few more rounds of “consolidation” chemotherapy to ensure all remaining cancer cells are gone [2].
Treatment for Advanced-Stage Disease (III/IV)
When the lymphoma has spread to other parts of the body, treatment focuses on intensive systemic chemotherapy [3]. Several regimens are used:
- DDGP (Dexamethasone, Cisplatin, Gemcitabine, Pegaspargase): This is currently a preferred frontline option. Research has shown it provides better survival rates and is easier for patients to tolerate than older, more intensive regimens [3].
- P-GEMOX (Pegaspargase, Gemcitabine, Oxaliplatin): Another effective and safe option often used for both newly diagnosed and relapsed cases [12].
- SMILE: A more intensive regimen that was once the gold standard. While effective, it often has higher toxicity and more side effects than DDGP [3].
New Frontiers: Immunotherapy
If the lymphoma does not respond to initial treatment (refractory) or comes back (relapsed), doctors may turn to PD-1 inhibitors [13]. These are immunotherapy drugs (like pembrolizumab or sugemalimab) that help your own immune system recognize and attack the cancer cells [14][15]. These treatments have shown great promise and are currently being studied to see if they should be used even earlier in the treatment process [16][17].
Common questions in this guide
Why is the standard CHOP chemotherapy not used for ENKTL?
What is the main chemotherapy drug used to treat ENKTL?
How is early-stage ENKTL usually treated?
What treatment options are available for advanced ENKTL?
Are there immunotherapy options for ENKTL?
Get notified when new evidence is published on Extranodal nasal NK/T cell lymphoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (17)
- 1
New Approaches for Treatment of Advanced Extranodal NK/T-Cell Lymphoma.
Yi W, Yang T, Lin S, et al.
Cancer management and research 2022; (14()):401-407 doi:10.2147/CMAR.S328846.
PMID: 35115837 - 2
Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: A French retrospective study.
Chaubard S, Marouf A, Lavergne D, et al.
British journal of haematology 2023; (201(4)):673-681 doi:10.1111/bjh.18689.
PMID: 36799516 - 3
DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China.
Li X, Cui Y, Sun Z, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research 2016; (22(21)):5223-5228 doi:10.1158/1078-0432.CCR-16-0153.
PMID: 27060152 - 4
NK/T Cell Lymphoma: Updates in Therapy.
Suzuki R
Current hematologic malignancy reports 2018; (13(1)):7-12 doi:10.1007/s11899-018-0430-5.
PMID: 29368155 - 5
Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?
Zhang X, Fu X, Dong M, et al.
Cancer cell international 2018; (18()):150 doi:10.1186/s12935-018-0644-6.
PMID: 30302057 - 6
ATP-binding cassette sub-family C member 4 (ABCC4) is overexpressed in human NK/T-cell lymphoma and regulates chemotherapy sensitivity: Potential as a functional therapeutic target.
Zhang X, Zhao L, Li X, et al.
Leukemia research 2015; (39(12)):1448-54.
PMID: 26499190 - 7
Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study.
Wang H, Wang L, Li C, et al.
The oncologist 2020; (25(11)):e1725-e1731 doi:10.1634/theoncologist.2020-0144.
PMID: 32627928 - 8
Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas.
Tse E, Au-Yeung R, Kwong YL
Expert review of hematology 2019; (12(11)):927-935 doi:10.1080/17474086.2019.1660640.
PMID: 31487202 - 9
Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
Yoon DH, Kim SJ, Jeong SH, et al.
Oncotarget 2016; (7(51)):85584-85591 doi:10.18632/oncotarget.11319.
PMID: 27542213 - 10
The diagnosis and management of NK/T-cell lymphomas.
Tse E, Kwong YL
Journal of hematology & oncology 2017; (10(1)):85 doi:10.1186/s13045-017-0452-9.
PMID: 28410601 - 11
Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
Oh D, Ahn YC, Kim SJ, et al.
International journal of radiation oncology, biology, physics 2015; (93(3)):677-83.
PMID: 26461010 - 12
Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.
Wang JH, Wang L, Liu CC, et al.
Oncotarget 2016; (7(20)):29092-101 doi:10.18632/oncotarget.8647.
PMID: 27093153 - 13
Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports.
Rivera-Francia VM, Failoc-Rojas VE, Villacorta-Carranza R, et al.
Leukemia & lymphoma 2024; (65(1)):37-47 doi:10.1080/10428194.2023.2264431.
PMID: 37794819 - 14
Efficacy and safety of PD-1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective study.
Tian J, Hao M, Liu Q, et al.
Hematological oncology 2023; (41(3)):396-406 doi:10.1002/hon.3116.
PMID: 36516297 - 15
PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas.
Xie W, Medeiros LJ, Li S, et al.
Biomedicines 2022; (10(7)) doi:10.3390/biomedicines10071587.
PMID: 35884893 - 16
Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma.
Chen Z, Huang H, Huang H, et al.
Leukemia 2024; (38(4)):829-839 doi:10.1038/s41375-024-02171-4.
PMID: 38378844 - 17
An evaluation of sugemalimab for the treatment of relapsed or refractory extranodal natural killer T-cell lymphoma.
Feng Y, Liu X, Yu J, et al.
Expert opinion on biological therapy 2025; (25(1)):9-14 doi:10.1080/14712598.2024.2444400.
PMID: 39702924
This page provides educational information on ENKTL treatment options. Always consult your oncologist to determine the best treatment plan for your specific stage and medical history.